The drugmaker is halting production of Excedrin Extra Strength and Excedrin Migraine. A spokesperson told WSYR the halt is due to “inconsistencies in how we transfer and weigh ingredients for Excedrin Migraine caplets and geltabs.”
“Based on the available data, GSK believes that the product does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare has voluntarily implemented a discontinuation of production and distribution,” the spokesperson said.
The drugmaker said it does not know when it will resume production of the two drugs it’s halting, but other Excedrin products are available.
Some pharmacies in Central New York are already running out of the discontinued Excedrin products, WSYR reported.
Read the full article here.
More articles on pharmacy:
Walgreens, CVS demands led Ohio Medicaid to drop 272 pharmacies, state says
How Civica Rx became a force in the generic drug industry: A timeline
10 most expensive drugs for Medicare Part D
Walgreens, CVS demands led Ohio Medicaid to drop 272 pharmacies, state says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.